GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Transcript and Link of Recording
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals India held an analyst/institutional investor meet on May 13, 2025, to discuss Q4 and Full Year FY2025 results. The company reported FY25 revenue of INR 3,723 crores (9% growth, volume-led), EBITDA of INR 1,169 crores (30% growth), and EBITDA margins expanding from 26% to 31%, supported by gross margin improvement and SG&A cost optimisation. The company announced upcoming launches of two oncology drugs — Jemperli (endometrial cancer) and Zejula (ovarian cancer) — marking entry into oncology as a new growth platform, alongside 19 ongoing global clinical trials in India to reduce drug launch lag. Management guided that margins are at a 'stabilization stage' and explicitly said investors should not expect further margin expansion beyond the 31% annual level, even though Q4 exited at 34%. A final dividend of INR 42 per share was declared, and the balance sheet remains strong with zero debt and ~INR 2,500 crores in cash.
Strong FY25 print and entry into oncology are positive for the long-term growth story, but the explicit management signal that margins have peaked at ~31% may limit further re-rating and cap near-term upside. The oncology launches and Shingrix scale-up remain the key forward catalysts for the stock.